Home Biosimilar Antibodies Immunology & Inflammation Interleukins Briakinumab (Anti-IL-12) (IL-12a & IL-12b)
For research use only. Not for use in humans.

Briakinumab (Anti-IL-12) (IL-12a & IL-12b)

Synonyms: IL12A， IL12B

Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD.

Briakinumab (Anti-IL-12) (IL-12a & IL-12b)

Quality Control

Batch: A294701 Purity: 99% Protein concentration: 6.182mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 KD.
References

Product Details

CAS No. 339308-60-0
Molecular Weight 143.86
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05928039 RECRUITING Crohn Disease University of Calgary 2023-10-25 PHASE4
NCT03366142 COMPLETED Drug: Ustekinumab LAD1 National Institute of Allergy and Infectious Diseases (NIAID) 2018-07-02 PHASE1; PHASE2
NCT02648581 COMPLETED Drug: Subcutaneous Ustekinumab Behçet Disease Assistance Publique - Hôpitaux de Paris 2017-06-14 PHASE2
NCT01999868 COMPLETED Drug: UST Placebo|Drug: ABA Placebo Psoriasis National Institute of Allergy and Infectious Diseases (NIAID) 2014-03-19 PHASE2
NCT01077362 COMPLETED Drug: placebo|Drug: ustekinumab 45 mg|Drug: ustekinumab 90 m Arthritis, Psoriatic Janssen Research & Development, LLC 2010-03 PHASE3
NCT00292396 COMPLETED Drug: Anti IL-12 monoclonal antibody/ABT-874|Drug: placebo Psoriasis AbbVie (prior sponsor, Abbott) 2005-11 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-06-11)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.